178 related articles for article (PubMed ID: 22314523)
21. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
22. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
[TBL] [Abstract][Full Text] [Related]
23. Morphine Increases Lamivudine- and Nevirapine-Induced Human Immunodeficiency Virus-1 Drug-Resistant Mutations In Vitro.
Liang B; Jiang J; Pan P; Chen R; Zhuang D; Zhao F; Chen H; Huang J; Su Q; Cao C; Li J; Liang H; Ye L
Microb Drug Resist; 2017 Apr; 23(3):285-293. PubMed ID: 27420739
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
Okamoto M; Okamoto T; Baba M
Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
[TBL] [Abstract][Full Text] [Related]
25. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Palmer S; Alaeus A; Albert J; Cox S
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):157-62. PubMed ID: 9462926
[TBL] [Abstract][Full Text] [Related]
26. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
27. Novel thiosemicarbazones derived from formyl- and acyldiazines: synthesis, effects on cell proliferation, and synergism with antiviral agents.
Easmon J; Heinisch G; Holzer W; Rosenwirth B
J Med Chem; 1992 Aug; 35(17):3288-96. PubMed ID: 1354751
[TBL] [Abstract][Full Text] [Related]
28. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.
Stránská R; Schuurman R; Nienhuis E; Goedegebuure IW; Polman M; Weel JF; Wertheim-Van Dillen PM; Berkhout RJ; van Loon AM
J Clin Virol; 2005 Jan; 32(1):7-18. PubMed ID: 15572000
[TBL] [Abstract][Full Text] [Related]
29. Potentiating effect of ribavirin on the anti-herpes activity of acyclovir.
Pancheva SN
Antiviral Res; 1991 Sep; 16(2):151-61. PubMed ID: 1665959
[TBL] [Abstract][Full Text] [Related]
30. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
[TBL] [Abstract][Full Text] [Related]
31. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
33. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
Kuritzkes DR; Shugarts D; Bakhtiari M; Poticha D; Johnson J; Rubin M; Gingeras TR; Kennedy M; Eron JJ
J Acquir Immune Defic Syndr; 2000 Jan; 23(1):26-34. PubMed ID: 10708053
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
35. Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.
Hoffmann D; Garcia AD; Harrigan PR; Johnston IC; Nakasone T; García-Lerma JG; Heneine W
PLoS One; 2011; 6(7):e22019. PubMed ID: 21799767
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
[TBL] [Abstract][Full Text] [Related]
37. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
Mayers DL
Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
[TBL] [Abstract][Full Text] [Related]
39. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
40. Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo.
Allers K; Knoepfel SA; Rauch P; Walter H; Opravil M; Fischer M; Günthard HF; Metzner KJ
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):377-85. PubMed ID: 17211280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
